HOME >> BIOLOGY >> NEWS
U-M and Israel launch major international cancer study

ANN ARBOR---MI Researchers at the University of Michigan and the KHC National Center of Cancer Control in Haifa, Israel, have been awarded a $4.8 million grant to study genetic aspects of colon cancer. The five-year study, funded by the National Cancer Institute, will examine how genetic susceptibility to cancer may be modified by diet, medications, and lifestyle.

The Molecular Epidemiology of Colorectal Cancer study will identify and interview more than 2,000 individuals in Israel who have colon cancer and compare them to a cancer-free group of equal size. Investigators hope to learn why some people who carry genes that increase their risk of colon cancer develop tumors while others with the same gene do not.

"Colon cancer is a complex disease, and genetic susceptibility is only part of the story," says Stephen Gruber, M.D., Ph.D., principal investigator of the study, and assistant professor of internal medicine and epidemiology in the U-M Health System. "Many people with a genetic susceptibility to colon cancer never develop the disease, and we need to figure out why. If we can recognize what protects those people who are most susceptible, it should help us learn how to do a better job preventing colon cancer in all populations."

Researchers elected to conduct the study in Israel because three different ethnic populations there have very different risks of colon cancer. Individuals of Ashkenazi Jewish descent have relatively high rates of colon cancer, whereas colon cancer is rare in people of Arabic descent. Sephardic Jews have an intermediate risk of colon cancer.

"It is not clear why different populations within Israel have such different risks of colon cancer, nor do we understand the influences of immigration," says Gadi Rennert, M.D., Ph.D., co-principal investigator of the study and director of the KHC National Center for Cancer Control at Carmel Medical Center and Technion in Haifa, Israel. "This study should provide insight into
'"/>

Contact: Peter Barkey
pbarkey@umich.edu
734-764-2220
University of Michigan
14-Jun-1999


Page: 1 2 3

Related biology news :

1. Israeli scientists reveal the plan of a key cellular machine
2. Study by Israeli scientists provides insight on DNA code
3. Desert science center aims to bridge rift between Jordan and Israel
4. Takeda Chemical Industries and Beth Israel Deaconess announce research agreement
5. Scientists identify a gene causing a fatal heart condition, common in an Israeli Bedouin tribe
6. Israeli scientists block the progression of Type I diabetes
7. Israeli scientists discover gene responsible for hereditary muscle disease prevalent among Jews of Persian descent
8. Israeli teams grows heart cells and insulin producing cells from human embryonic stem cells
9. Israeli fertility experts call for international chromosome registry
10. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
11. Researchers develop white wine with cholesterol-lowering benefits, discover Israeli wines healthier than French wines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: and Israel launch major international cancer study

(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: